Pimecrolimus Interferes With the Therapeutic Efficacy of Human Mesenchymal Stem Cells in Atopic Dermatitis by Regulating NFAT-COX2 Signaling

    August 2021 in “ Stem Cell Research & Therapy ”
    Nari Shin, Namhee Jung, Seung‐Eun Lee … Kyung‐Sun Kang
    Studysummary This study found that coadministration of pimecrolimus may interfere with the therapeutic efficacy of mesenchymal stem cell therapy in atopic dermatitis.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on stemcellres.biomedcentral.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases Frontiers in Cell and Developmental Biology · 2021